Reyes Bernabé

Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer

Mariano Provencio, Ernest Nadal, J.L. González-Larriba et al. · New England Journal of Medicine · 2023 · 450 citations · Full text

Medicine, Oncology, Surgery +17

Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial.

Mariano Provencio-Pulla, Ernest Nadal, J.L. González-Larriba et al. · Journal of Clinical Oncology · 2022 · 63 citations

Medicine, Oncology, Pharmacology +17

Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced <i>EGFR</i>-Mutant Non–Small-Cell Lung Cancer

Jordi Remón, Benjamin Besse, Santiago Ponce Aix et al. · Journal of Clinical Oncology · 2024 · 31 citations · Full text

Medicine, Oncology, Pharmacology +15

Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A

Benjamin Besse, Kōichi Goto, Yongsheng Wang et al. · Journal of Thoracic Oncology · 2025 · 27 citations · Full text

Medicine, Oncology, Pharmacology +15

KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.

Vanesa Gregorc, María González‐Cao, Stefania Salvagni et al. · Journal of Clinical Oncology · 2024 · 26 citations

Medicine, Oncology, Pharmacology +17